Aciceda Therapeutics LogoHome
Home Our Approach Pipeline and Programs Publications News and Events Careers About Us Contact
View Linkedin View Twitter

OphthalmologyClinical

Diabetic Macular EdemaAVD-104

Aviceda’s high affinity ligand engages Siglecs to decrease neutrophil and macrophage activation and reduce inflammatory mediators to reduce diabetic macular edema.

Background image Ophthalmology Geographic Atrophy - AVD-104 Ophthalmology Geographic Atrophy - AVD-104 Background image Ophthalmology Diabetic Macular Edema - AVD-104 Ophthalmology Diabetic Macular Edema - AVD-104 Background image Ophthalmology Diabetic retinopathy - AVD-302 Ophthalmology Diabetic retinopathy - AVD-302 Background image Fibrosis Myelofibrosis Fibrosis Myelofibrosis Background image Inflammation Lung inflammation Inflammation Lung inflammation Background image Neuroinflammation CNS injury Neuroinflammation CNS injury Background image Oncology Solid tumors Oncology Solid tumors